I am grateful that Drs Elder, Rahman, and McLay1 have shared with us the results of macular field testing using the HVF-10 paradigm in patients using hydroxychloroquine. It emphasizes that toxicity can develop in patients taking a “safe” dosage and once again raises the question of what constitutes proper vigilance for our patients. I think the real question, however, remains how quickly can a patient go from no damage to damage that is either visually disabling or that will progress to a visually disabling level. This would help determine the interval of testing.
Bienfang DC. Screening for Hydroxychloroquine Toxicity. Arch Ophthalmol. 2007;125(11):1585. doi:10.1001/archopht.125.11.1585-a